TrialSignal
Clinical trial intelligence report
An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03334786-Jul 28, 2026
NCT ID
NCT03334786
Status
TERMINATED
Phase
Phase 1/2
Sponsor
Flex Pharma, Inc.
Executive brief
Investment-Ready Snapshot
Flex Pharma, Inc. initiated the FLX-787-107 study to evaluate the safety and efficacy of FLX-787-ODT for treating fasciculations in ALS patients. The study's termination indicates a significant setback in the development of this formulation, potentially impacting Flex Pharma's market position in the neuromuscular disorder space. The ALS market is characterized by limited treatment options, and any effective therapy could capture substantial market share. However, the cessation of this study raises concerns regarding the viability of FLX-787-ODT and may necessitate a reevaluation of Flex Pharma's pipeline and strategic direction. Competitors in the ALS treatment landscape may benefit from this development halt, as they could accelerate their own programs to fill the unmet need.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03334786
Indication
Amyotrophic Lateral Sclerosis
Modality
small molecule
Target
FLX-787-ODT is designed to target neuromuscular excitability, specifically aimed at reducing fasciculations in ALS patients.
Intervention
FLX-787-ODT
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.